TOP STORY Systems Biology Helps to Understand Hematopoiesis Researchers combined experimental data with mathematical models in a systems biology approach to study the effect of erythropoietin level on hematopoietic cells. [Press release from EurekAlert! discussing online prepublication in Science]
|
|
SCIENCE NEWS Early Clamping May Interrupt Humankind’s First “Natural Stem Cell Transplant,” the Researchers Report Delaying clamping the umbilical cord for a slightly longer period of time allows more umbilical cord blood to transfer from mother to infant and, with that critical period extended, many good physiological “gifts” are transferred through ‘nature’s first stem cell transplant’ occurring at birth. [Press release from the University of South Florida discussing online prepublication in the Journal of Cellular and Molecular Medicine] Drug in New Class of Targeted Therapies Shows Early Promise Against Blood-Related Cancers A Phase I clinical trial of SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases, demonstrated the drug’s safety and potential clinical action against advanced chronic lymphocytic leukemia. [Press release from Hackensack University Medical Center discussing online prepublication in the Journal of Clinical Oncology] Celgene’s Revlimid Positive in Maintenance Trials Two major studies of Celgene Corp’s multiple myeloma drug Revlimid showed that when taken as maintenance therapy following stem cell transplantation it reduced the risk of disease progression by more than 50 percent. [Reuters Press Release]
|
|
CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal) LABORATORY RESEARCH Covering a Broad Dynamic Range: Information Processing at the Erythropoietin Receptor Researchers show by mathematical modeling of quantitative data and experimental validation that rapid ligand depletion and replenishment of cell surface receptor are characteristic features of the erythropoietin receptor. [Science] Glutaredoxin 5 Deficiency Causes Sideroblastic Anemia by Specifically Impairing Heme Biosynthesis and Depleting Cytosolic Iron in Human Erythroblasts Researchers report that GLRX5 is essential for iron-sulfur cluster biosynthesis and the maintenance of normal mitochondrial and cytosolic iron homeostasis in human cells. [J Clin Invest] SENP1-Mediated GATA1 DeSUMOylation is Critical for Definitive Erythropoiesis Collectively, researchers conclude that SENP1 promotes GATA1 activation and subsequent erythropoiesis by deSUMOylating GATA1. [J Exp Med] Regulatory Functions of TRAIL in Hematopoietic Progenitors: Human Umbilical Cord Blood and Murine Bone Marrow Transplantation It is concluded that TRAIL does not trigger apoptosis in hematopoietic progenitors, and upregulation of its cognate receptors under stress conditions mediates tropic signaling that supports recovery from hypoplasia. [Leukemia] IL-34 and M-CSF Share the Receptor Fms But Are Not Identical in Biological Activity and Signal Activation The findings indicate that macrophage phenotype and function are differentially regulated even at the level of the single receptor, Fms. [Cell Death Differ] CXCR4-Independent Rescue of the Myeloproliferative Defect of the Gata1(Low) Myelofibrosis Mouse Model by Aplidin® In this paper, researchers used the hypomorphic Gata1(low) mouse model of primary myelofibrosis, the most severe of these neoplasms, to test the hypothesis that defective marrow hemopoiesis and development of extramedullary hematopoiesis in myelofibrosis is due to insufficient p27(Kip1) activity and is treatable by Aplidin®, a cyclic depsipeptide that activates p27(Kip1) in several cancer cells. [J Cell Physiol] Expression of microRNA-451 in Normal and Thalassemic Erythropoiesis The results suggest that early erythroid progenitors in beta-thalassemia have a dysregulated miRNA-451 expression program, and analysis of microRNA is a relevant approach to determine abnormalities of erythropoiesis. [Ann Hematol] CLINICAL RESEARCH Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Hematologic Malignancies After Dose-Escalated Treosulfan/Fludarabine Conditioning Treosulfan was introduced recently as a conditioning agent for allogeneic blood stem-cell transplantation. The favorable nonhematologic toxicity profile at 3 x 10 g/m(2) was the basis for dose escalation in this prospective, multicenter trial. [J Clin Oncol] A Molecular Classifier for Predicting Future Graft Loss in Late Kidney Transplant Biopsies In an attempt to identify molecules that could provide this information, researchers used micorarrays to analyze gene expression in 105 for-cause biopsies taken between 1 and 31 years after transplantation. [J Clin Invest]
|
|
POLICY NEWS House Nixes More Research Spending in COMPETES Bill Catching the Democratic leadership by surprise, members voted 292 to 126 to block passage of a 5-year authorization bill that would have provided healthy increases in the research and education budgets of the National Science Foundation and research programs at the Department of Energy and the Department of Commerce. [House of Representatives, United States] NIH Wants More (Not Total) Disclosure of Financial Conflicts The federal government proposed an overhaul of regulations covering financial conflicts of interest in biomedical research. The rules would expand the amount of information that researchers must report to their institutions, make some of it public, and require that more details than in the past be submitted privately to the National Institutes of Health. [National Institutes of Health, United States] NIH Requests Comments on the Proposed Rule Applicable to Regulations on the Responsibility of Applicants for Promoting Objectivity in Research for which Public Health Service Funding is Sought and Responsible Prospective Contractors (NOT-OD-10-099) [National Institutes of Health, United States] Notice of Format Clarification and Frequently Asked Questions (FAQs) for Funding Opportunity Announcement (FOA): RFA-HL-11-006, Next Generation Genetic Association Studies (U01) (NOT-HL-10-110) [National Institutes of Health, United States] Responsibility of Applicants for Promoting Objectivity in Research for Which Public Health Service Funding Is Sought and Responsible Prospective Contractors; Proposed Rule (Docket Number: NIH-2010-0001) [National Institutes of Health, United States] Charter of the Blood Products Advisory Committee (Update) [Food and Drug Administration, United States] FDA Transparency Initiative: Draft Proposals for Public Comment Regarding Disclosure Policies of the U.S. Food and Drug Administration; Availability [Docket No. FDA-2009-N-0247] [Food and Drug Administration, United States]
|
|
EVENTS
International Scientific Symposium; Stem Cells in Biology and Disease May 26-28, 2010 Lisbon, Portugal International Society for Stem Cell Research (ISSCR) 8th Annual Meeting June 16-19, 2010 San Francisco, United States XXXIst International Congress of the International Society of Blood Transfusion (ISBT) in joint cooperation with the 43rd Congress of the German Society for Transfusion Medicine and Immunohematology (DGTI) June 26-July 1, 2010 Berlin, Germany The European Molecular Biology Organization (EMBO) Meeting 2010 September 4-7, 2010 Barcelona, Spain Stem Cells USA & Regenerative Medicine Congress 2010 September 13-15, 2010 Philadelphia, United States Society for Hematology and Stem Cells (ISEH) 2010 Meeting September 15-18, 2010 Melbourne, Australia Stem Cells and Regeneration October 3-9, 2010 Woods Hole, United States American Association of Blood Banks (AABB) Annual Meeting 2010 October 9-12, 2010 Baltimore, United States Fraunhofer Life Science Symposium Leipzig 2010 October 29-30, 2010 Leipzig, Germany 52nd American Society of Hematology (ASH) Annual Meeting and Exposition December 4-7, 2010 Orlando, United States Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
JOB OPPORTUNITIES
Senior Scientist – Magnetic Cell Separation (STEMCELL Technologies) Business Development Manager Europe – Cell Therapy Products (Pall Corporation) Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)” target=”_blank” href=”http://cl.exct.net/?qs=ee4a9b163e6ccad6c08f6ca4355f928a877d7c021b02577c2796a427b0802610″>Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza) Recruit Top Talent Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News. Visit here to post your career opportunities.
Have we missed an important article or publication in Hematopoiesis News? Click here to submit!
|
| |
|